First Time Loading...

Editas Medicine Inc
NASDAQ:EDIT

Watchlist Manager
Editas Medicine Inc Logo
Editas Medicine Inc
NASDAQ:EDIT
Watchlist
Price: 5.46 USD -2.5% Market Closed
Updated: Apr 24, 2024

Editas Medicine Inc
Operating Income

Last Value
3-Years CAGR
5-Years CAGR
Quarterly
Annual
TTM
|

Editas Medicine Inc
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Editas Medicine Inc
NASDAQ:EDIT
Operating Income
$-169.2m
CAGR 3-Years
-8%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Income
$16.6B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$9.3B
CAGR 3-Years
32%
CAGR 5-Years
2%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Operating Income
$8.2B
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$3.8B
CAGR 3-Years
10%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
19%

See Also

What is Editas Medicine Inc's Operating Income?
Operating Income
-169.2m USD

Based on the financial report for Dec 31, 2023, Editas Medicine Inc's Operating Income amounts to -169.2m USD.

What is Editas Medicine Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-8%

Over the last year, the Operating Income growth was 25%. The average annual Operating Income growth rates for Editas Medicine Inc have been -8% over the past three years , -8% over the past five years .